Printer Friendly

MOLECULAR BIOSYSTEMS RECEIVES ALLOWANCE ON U.S. PATENT FOR ORAL ULTRASOUND AGENT

 MOLECULAR BIOSYSTEMS RECEIVES ALLOWANCE ON
 U.S. PATENT FOR ORAL ULTRASOUND AGENT
 SAN DIEGO, Feb. 5 /PRNewswire/ -- Molecular Biosystems Inc. (NYSE: MB) (MBI) announced today that the U.S. Patent Office has allowed the company's patent application for its orally administered ultrasound contrast agent.
 MBI's oral contrast agent, currently in preclinical trials, is being designed to improve anatomic definition during diagnostic abdominal ultrasound scanning. No such ultrasound agents are currently commercially available. It is estimated that there are approximately 4 million abdominal ultrasound scans performed annually in the United States.
 "We are gratified to receive such prompt action on this patent from the U.S. Patent Office," stated Kenneth J. Widder, M.D., MBI's chairman and chief executive officer. "We are aggressively moving ahead with the agent and hope to start clinical trials by the end of this year," he further stated.
 Molecular Biosystems Inc., based in San Diego, is a leader in the development and manufacturing of contrast agents for medical imaging, including ultrasound and magnetic resonance imaging. Its flagship product, Albunex (R), is currently in the final stages of the FDA's pre-market approval process. MBI's shares are listed on the New York Stock Exchange under the symbol "MB."
 -0- 2/5/92
 /CONTACT: Beth Field Wallace of Molecular Biosystems, 619-452-0681/
 (MB) CO: Molecular Biosystems Inc. ST: California IN: MTC SU:


JL-EH -- SD002 -- 7013 02/05/92 08:31 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Feb 5, 1992
Words:231
Previous Article:CRI LIQUIDATING REIT EXPECTS TO DISTRIBUTE MORTGAGE PROCEEDS IN TWO PAYMENTS
Next Article:CCAIR REPORTS PROFIT AND SUMMER GROWTH PLANS
Topics:


Related Articles
MOLECULAR BIOSYSTEMS ACQUIRES LICENSE TO CT IMAGING AGENT TECHNOLOGY
FDA ADVISORY PANEL RECOMMENDS APPROVAL FOR MBI'S ALBUNEX(R)
SHERRY L. MESMAN APPOINTED AS CHIEF FINANCIAL OFFICER OF MOLECULAR BIOSYSTEMS
MBI SUED BY COMPETITOR OVER ORAL AGENT
ALBUNEX(R) RECEIVES FDA APPROVAL; FIRST CONTRAST AGENT FOR ULTRASOUND
MOLECULAR BIOSYSTEMS, MALLINCKRODT GROUP ANNOUNCE NEW ALLIANCE
SONUS Pharmaceuticals Announces Dismissal of MBI and Mallinckrodt Lawsuit To Invalidate SONUS Patents

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters